005250.KS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 09:30):

Stats
Dzisiejszy wolumen	0.00
Średni wolumen	60 812.00
Kapitalizacja rynkowa	714.45B
EPS	KRW0 ( 2024-02-13 )
Następna data zysków	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW14.83 (0.09%)

Wolumen Korelacja

Długi: 0.01 (neutral)

Krótki: -0.41 (neutral)

Signal:(46.446) Neutral

Green Cross Holdings Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Green Cross Holdings Korelacja - Waluta/Towar

0.32
( neutral )

0.04
( neutral )

-0.15
( neutral )

0.58
( weak )

0.57
( weak )

0.60
( weak )

Green Cross Holdings Finanse

Annual	2023
Przychody:	KRW2 057.94B
Zysk brutto:	KRW563.69B (27.39 %)
EPS:	KRW-1 192.38

FY	2023
Przychody:	KRW2 057.94B
Zysk brutto:	KRW563.69B (27.39 %)
EPS:	KRW-1 192.38

FY	2022
Przychody:	KRW2 079.56B
Zysk brutto:	KRW698.34B (33.58 %)
EPS:	KRW1 297.25

FY	2021
Przychody:	KRW1 840.56B
Zysk brutto:	KRW628.54B (34.15 %)
EPS:	KRW1 759.01

Financial Reports:

No articles found.

Green Cross Holdings

Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies. Green Cross Holdings was founded in 1967 and is headquartered in Yongin, South Korea.